Identification

Symbol
AMT
ISIN code
NL0000886968
Exchange / Market
Euronext
Trading location
Amsterdam
Products family
Stocks
Market organization
EuronextAmsterdam
ICB
Biotechnology
Activity description

AMT (Amsterdam Molecular Therapeutics) specializes in the development of gene therapy products intended for treating serious, often rare, diseases with a major medical need. The group's products are based on introducing genes into target organs and tissues in order to accomplish the long-term expression of the genes and correct the genetic defects causing the disease. AMT has a portfolio of 5 products: 3 in late stage pre-clinical development (for treating Parkinson's Disease, Duchenne Muscular Dystrophy and Porphyria), 1 in the Phase I/II clinical study (for treating Hemophilia B) and 1 in the marketing phase (Glybera® for treating lipoprotein lipase deficiency).

Website address
www.amtbiopharma.com
Issuer website
www.amtbiopharma.com

Operation

IPO date
Wed 06/10/2010
IPO price
2.03
IPO type
New Issue Special Session
Catégorie
New Issue Special Session
Operation procedure

OFFER SHARES